Selank and Semax are unrelated peptides, each studied on its own

How do Selank and Semax differ?

Selank and Semax are structurally unrelated peptides with separate mechanism stories. Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory peptide. Semax is a fragment of ACTH(4-10), the adrenocorticotropic hormone, modified for stability.

Selank has small human trials ^[1]⁠^[2]. None of the studies cited below tests Semax directly.

How is Selank proposed to work?

Selank's proposed anxiolytic action runs through GABAergic and serotonergic modulation, with downstream effects on BDNF expression in the hippocampus and prefrontal cortex ^[4].

Selank also carries an immunomodulatory signature distinct from typical anxiolytics. In one open-label study, Selank normalized Th1/Th2 cytokine balance and restored CD4+/CD8+ T-cell ratios in patients with anxiety-asthenic disorders, and it suppressed IL-6 expression in cells from depressed patients in vitro ^[2]. That is an unusual mechanism for an anxiolytic. It comes from one single-site study that reports no sample size and has no international replication ^[2].

What human trials have tested Selank?

Selank has been tested in two small Russian trials, of 62 and 30 patients, plus one immune-marker study, and none has been independently replicated outside Russia ^[1]⁠^[2].

The strongest piece is a randomized trial comparing intranasal Selank against medazepam, a benzodiazepine, in 62 patients with generalized anxiety disorder or neurasthenia. Selank produced anxiolytic effects on the Hamilton and Zung scales comparable to the benzodiazepine, and it also showed antiasthenic and psychostimulant effects the benzodiazepine did not have ^[1]. That makes it a true RCT, which is more than most peptides in this space can claim. It is also small, single-site, published in a Russian-language journal, and lacks any independent multi-center follow-up in an international journal.

The second study was open-label against a waitlist control. Two weeks of Selank reduced somatic symptom scores and alcohol misuse scores in patients with adjustment disorder, with benefits persisting at four weeks. Open-label and waitlist-controlled designs are vulnerable to placebo and expectancy effects in ways blinded RCTs are not.

Selank clears the bar of small-trial evidence for a specific mechanism, which puts it ahead of bro-science. It does not clear the bar of internationally replicated clinical evidence. Grade C fits: better than pure anecdote, well short of an approved indication. The Selank anxiety trial record is covered in more depth separately.

What do animal studies show for Selank?

Animal studies give Selank more robust and more numerous evidence than its human trials, with consistent effects on depression-related behavior and alcohol-related memory impairment in rats and mice ^[3]⁠^[4].

Selank reversed depression-related behaviors in genetically anxious rats and reduced immobility in a standard antidepressant screening test in mice ^[3]. In a separate rat study, Selank prevented alcohol-related memory impairment while normalizing hippocampal and prefrontal BDNF ^[4].

These findings are consistent and mechanistically clean, but they come from rodents at defined mg/kg doses, not from humans using a nasal spray.

What evidence supports Semax?

None of the studies cited below tests Semax directly, so the case for Semax in a nootropic stack rests on mechanism carried over from general pharmacology, not on a study anyone can point to.

Semax's background mechanism, per the general research literature on ACTH fragments, centers on raising BDNF and NGF, with neuroprotective and nootropic framing. Semax's Russian clinical history covers stroke and cognitive impairment, a different population and dose from nasal-spray nootropic use, and none of the studies cited below covers that history.

The missing evidence for "focus and mood" nootropic use should weigh heavily in how you read vendor claims for Semax. Semax's evidence for cognitive enhancement gets its own analysis.

Has any study tested Selank and Semax together?

No study has tested Selank with Semax, at any dose, in any species ^[1]⁠^[2]⁠^[3]⁠^[4]. Every study cited below tests Selank alone, Selank against a benzodiazepine, or Selank in rodents.

The claim that the combination produces additive or synergistic anxiolytic-plus-cognitive effects is an inference from two separate mechanism stories: GABA, serotonin and immune effects for Selank, and BDNF and NGF for Semax. The stories are stitched together because both peptides raise BDNF through different pathways. That is plausible, and it is not measured.

No pharmacokinetic study establishes whether co-administering two peptides intranasally changes absorption, degradation, or effective dose for either one. "Synergy" in stack write-ups is a marketing word doing the work a citation should do. The general principle is set out in why multi-ingredient stacks need evidence per component.

Where do Selank and Semax dosing protocols come from?

The 200 to 600 mcg doses and 2 to 4 week cycles circulating online come from vendor material and forum consensus, with no traceable origin in the studies cited below.

The Selank RCT used intranasal Selank without specifying a per-spray consumer dose comparable to vendor products ^[1]. Nasal pharmacokinetics for either peptide at consumer doses are not established in any study cited below.

Intranasal delivery depends heavily on formulation, mucosal contact time, and enzymatic degradation in the nasal cavity. All three vary by product, and none is characterized for research-chemical-grade material. For background on the route itself, see how nasal peptides reach the brain.

What are the risks of using Selank and Semax?

Purity and sterility are the largest practical risks of Selank and Semax.

Selank and Semax are unapproved for any use in the US. Research-chemical suppliers manufacture them with no standardized quality control and sell them explicitly as "not for human consumption." A contaminated or under-dosed vial changes the risk-benefit calculation far more than anything in the mechanism data. Long-term safety in humans, at any dose or duration, has no Western dataset behind it at all.

Reported side effects from informal use include nasal irritation, burning or congestion, mild fatigue or drowsiness, headache, and altered taste or post-nasal drip. None of these reports comes from the controlled trials. They are accumulated real-world reporting, and they deserve that weight: neither dismissed nor treated as clinical-grade safety data.

What does the Selank and Semax stack amount to?

The Selank and Semax stack combines two separately under-evidenced compounds on the strength of a mechanism story, sourced from a supply chain with no purity guarantee.

Selank has a real but narrow human evidence base: one RCT against an active comparator ^[1], one open-label trial against waitlist control, and consistent rodent mechanism data ^[3]⁠^[4]. Semax's place in the stack rests on mechanism plausibility, not on a study anyone can cite for the nootropic-stack use case. The combination has zero dedicated evidence, human or animal.

That is a different risk profile from "clinically studied anxiolytic peptide," and it deserves to be described that way.